KBC Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.24M | Sell |
17,011
-15,390
| -47% | -$2.04M | 0.01% | 638 |
|
|
2025
Q4 | $4.6M | Buy |
32,401
+17,835
| +122% | +$2.58M | 0.01% | 481 |
|
|
2025
Q3 | $2.04M | Hold |
14,566
| – | – | ﹤0.01% | 591 |
|
|
2025
Q2 | $1.83M | Buy |
14,566
+731
| +5% | +$83.8K | ﹤0.01% | 600 |
|
|
2025
Q1 | $1.53M | Sell |
13,835
-495
| -3% | -$62.7K | ﹤0.01% | 628 |
|
|
2024
Q4 | $1.96M | Sell |
14,330
-4,642
| -24% | -$574K | 0.01% | 690 |
|
|
2024
Q3 | $2.19M | Buy |
18,972
+8,332
| +78% | +$1.14M | 0.01% | 605 |
|
|
2024
Q2 | $1.47M | Buy |
10,640
+152
| +1% | +$20.8K | ﹤0.01% | 625 |
|
|
2024
Q1 | $1.45M | Sell |
10,488
-94
| -0.9% | -$12.8K | ﹤0.01% | 628 |
|
|
2023
Q4 | $1.39M | Sell |
10,582
-8,270
| -44% | -$952K | ﹤0.01% | 651 |
|
|
2023
Q3 | $2.12M | Sell |
18,852
-12,685
| -40% | -$1.34M | 0.01% | 579 |
|
|
2023
Q2 | $2.97M | Buy |
31,537
+3,384
| +12% | +$331K | 0.01% | 543 |
|
|
2023
Q1 | $2.85M | Sell |
28,153
-808
| -3% | -$84.1K | 0.01% | 593 |
|
|
2022
Q4 | $3.46M | Buy |
28,961
+25,979
| +871% | +$3.04M | 0.02% | 503 |
|
|
2022
Q3 | $317K | Sell |
2,982
-42
| -1% | -$4.26K | ﹤0.01% | 845 |
|
|
2022
Q2 | $295K | Buy |
3,024
+185
| +7% | +$17.1K | ﹤0.01% | 870 |
|
|
2022
Q1 | $266K | Sell |
2,839
-6,239
| -69% | -$529K | ﹤0.01% | 974 |
|
|
2021
Q4 | $773K | Sell |
9,078
-3,103
| -25% | -$285K | ﹤0.01% | 771 |
|
|
2021
Q3 | $1.17M | Sell |
12,181
-12,181
| -50% | -$1.15M | ﹤0.01% | 739 |
|
|
2021
Q2 | $2.37M | Hold |
24,362
| – | – | ﹤0.01% | 745 |
|
|
2021
Q1 | $2.37M | Hold |
24,362
| – | – | ﹤0.01% | 729 |
|
|
2020
Q4 | $12.8M | Hold |
24,362
| – | – | 0.01% | 728 |
|
|
2020
Q3 | $2.34M | Hold |
24,362
| – | – | 0.01% | 683 |
|
|
2020
Q2 | $2.97M | Buy |
24,362
+19,235
| +375% | +$2.13M | 0.01% | 621 |
|
|
2020
Q1 | $444K | Hold |
5,127
| – | – | ﹤0.01% | 873 |
|
|
2019
Q4 | $551K | Buy |
+5,127
| New | +$537K | ﹤0.01% | 1076 |
|
|
2019
Q3 | – | Sell |
-110
| Closed | -$10K | – | 1493 |
|
|
2019
Q2 | $10K | Hold |
110
| – | – | ﹤0.01% | 1436 |
|
|
2019
Q1 | $10K | Hold |
110
| – | – | ﹤0.01% | 1394 |
|
|
2018
Q4 | $8K | Hold |
110
| – | – | ﹤0.01% | 1294 |
|
|
2018
Q3 | $14K | Hold |
110
| – | – | ﹤0.01% | 1374 |
|
|
2018
Q2 | $11K | Hold |
110
| – | – | ﹤0.01% | 1280 |
|
|
2018
Q1 | $9K | Buy |
+110
| New | +$9.29K | ﹤0.01% | 1265 |
|
Other funds holding NBIX
VPM
VCM
KBC Group's NBIX Position: Q1 2026 in Review
KBC Group reduced its Neurocrine Biosciences (NBIX) stake by 47% in Q1 2026, selling an estimated $2.04M and leaving 17,011 shares worth $2.24M. The position accounts for 0.01% of the portfolio, ranked #638.
KBC Group first reported a position in NBIX in Q1 2018 and has held it in 32 quarters since. The position peaked at $12.8M in Q4 2020. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- KBC Group held 17,011 shares of Neurocrine Biosciences worth $2.24M as of Q1 2026.
- KBC Group sold 15,390 Neurocrine Biosciences shares in Q1 2026, an estimated $2.04M.
- Neurocrine Biosciences made up 0.01% of KBC Group's portfolio in Q1 2026, its #638 holding.
- KBC Group first reported a position in Neurocrine Biosciences in Q1 2018 and has held it in 32 quarters since.
- KBC Group's Neurocrine Biosciences position peaked at $12.8M in Q4 2020.
- 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.